Advances in Interventional Radiology for Oncological Management

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 31 July 2026 | Viewed by 547

Editors


E-Mail Website
Guest Editor
Mayo Clinic, 5777 E. Mayo Blvd., Phoenix, AZ 85054, USA
Interests: interventional radiology
Mayo Clinic, 5777 E. Mayo Blvd., Phoenix, AZ 85054, USA
Interests: interventional radiology

Special Issue Information

Dear Colleagues,

This Special Issue of Interventional Oncology will highlight the rapidly evolving role of minimally invasive image-guided therapies in cancer care. Interventional oncology (IO) has emerged as the “fourth pillar” of oncology, complementing surgery, medical oncology, and radiation oncology. This Special Issue will cover cutting-edge techniques including tumor ablation, embolization, and advanced catheter-directed therapies, alongside their integration into systemic treatments such as immunotherapy and targeted agents. We will explore novel technologies, imaging biomarkers, and AI-driven solutions to enhance precision, efficacy, and safety. Contributions will emphasize clinical outcomes, translational research, multidisciplinary collaboration, and future directions in IO. By gathering perspectives from leading experts, this Special Issue will provide a comprehensive overview of current innovations and chart a path forward in the effort to improve survival and quality of life in patients with cancer.

Dr. Alex L. Wallace
Dr. Merve Ozen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interventional oncology
  • tumor ablation
  • embolization
  • image-guided therapy
  • personalized medicine
  • translational research
  • cancer care

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 3664 KB  
Article
Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting
by Linhao Ran, Jiangwei Chen, Huan Liang, Jiajian Xie, Weichen Fu, Dichun Yang, Fan Li, Ying Liu and Li Jiang
Curr. Oncol. 2026, 33(7), 402; https://doi.org/10.3390/curroncol33070402 (registering DOI) - 5 Jul 2026
Viewed by 141
Abstract
Background: The incremental value of iodine-125 (I-125) seed implantation in advanced refractory lung squamous cell carcinoma (LUSC) with hemoptysis treated with bronchial artery chemoembolization (BACE) and immunotherapy remains unclear. Methods: This retrospective cohort study included 90 patients treated between June 2023 and June [...] Read more.
Background: The incremental value of iodine-125 (I-125) seed implantation in advanced refractory lung squamous cell carcinoma (LUSC) with hemoptysis treated with bronchial artery chemoembolization (BACE) and immunotherapy remains unclear. Methods: This retrospective cohort study included 90 patients treated between June 2023 and June 2025. Patients receiving BACE plus immunotherapy were classified according to whether I-125 seed implantation was performed within 7 days after BACE: G1, BACE plus immunotherapy (n = 42), and G2, BACE, I-125 seed implantation, and immunotherapy (n = 48). Inverse probability of treatment weighting (IPTW) served as the primary adjustment method. Results: After IPTW, baseline covariates were well balanced; propensity score matching yielded 26 patients per group. Compared with G1, G2 was associated with longer hemoptysis-free survival (not reached vs. 11 months; HR = 0.34, 95% CI 0.18–0.64, p < 0.05), overall survival (19 vs. 14 months; HR = 0.26, 95% CI 0.15–0.44, p < 0.05), and progression-free survival (12 vs. 9 months; HR = 0.34, 95% CI 0.21–0.56, p < 0.05). The 6-month objective response rate (ORR) and disease control rate (DCR) were higher in G2, whereas no significant difference in 24-h hemostasis or recorded grade 3 or higher adverse events was observed. Conclusions: Adding I-125 seed implantation to BACE plus immunotherapy was associated with improved outcomes in selected patients, and prospective validation is warranted. Full article
(This article belongs to the Special Issue Advances in Interventional Radiology for Oncological Management)
Show Figures

Graphical abstract

Back to TopTop